Advertisement

Helicobacter pylori and macrolides

  • Francis Mégraud
Chapter
Part of the Milestones in Drug Therapy MDT book series (MDT)

Abstract

A considerable amount of data gathered since 1982 has shown that Helicobacter pylori infection is responsible for most stomach diseases [1]. The primum movens of H. pylori is the most common type of gastritis found. This condition constitutes the background for diseases such as gastric and duodenal ulcers [2], as well as gastric lymphoma and carcinoma [3], which may occur when additional factors from either the host or the environment are present.

Keywords

Proton Pump Inhibitor Triple Therapy Antimicrob Agent Eradication Rate Macrolide Resistance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. 1.
    Warren JR, Marshall BJ (1983) Unidentified curved bacilli on gastric epithelium in active gastritis. Lancet i: 1273Google Scholar
  2. 2.
    Megraud F, Lamouliatte H (1992) Helicobacter pylori and duodenal ulcer: evidence suggesting causation. Dig Dis Sci 37: 769–772PubMedCrossRefGoogle Scholar
  3. 3.
    International Agency for Research on Cancer (1994) Monographs on the evaluation of carcino-genic risk to humans: schistosomes, liver flukes and Helicobacter pylori. International Agency for Research on Cancer, Lyon: 177–241Google Scholar
  4. 4.
    Lambert T, Megraud F, Gerbaud G, Courvalin P (1986) Susceptibility of Campylobacter pyloridis to 20 antimicrobial agents. Antimicrob Agents Chemother 30: 510–511PubMedCrossRefGoogle Scholar
  5. 5.
    Darmaillac V, Bouchard S, Lamouliatte H, Megraud F (1995) Macrolides and Helicobacter pylori determination of MICs and effect of pH. Gut 37 (supl.1): A91Google Scholar
  6. 6.
    Hardy DJ, Hanson CW, Hensey DM, Beyer JM, Fernandes PB (1988) Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones. J Antimicrob Chemother 22: 631–636PubMedCrossRefGoogle Scholar
  7. 7.
    Goldman RC, Zakula D, Flamm R, Beyer J, Capobianco J (1994) Tight binding of clarithromycin, its 14-(R)-hydroxy metabolite, and erythromycin to Helicobacter pylori ribosomes. Antimicrob Agents Chemother 38: 1496–1500PubMedCrossRefGoogle Scholar
  8. 8.
    Matysiak-Budnik T, Puzin C, Heyman M, Megraud F (2001) In vitro transfer of clarithromycin and amoxycillin across the epithelial barrier using labeled antibiotics. J Antimicrob Chemother (submitted)Google Scholar
  9. 9.
    Evans DG, Evans D Jr, Graham DY (1992) Adherence and internalization of Helicobacter pylori by Hep-2 cells. Gastroenterology 102: 1557–1567PubMedGoogle Scholar
  10. 10.
    Hulten K, Rigo R, Gustafsson I, Engstrand L (1996) New pharmacokinetic in vitro model for studies of antibiotics activity against intracellular microorganisms. Antimicrob Agents Chemother 40: 2727–2731PubMedGoogle Scholar
  11. 11.
    Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC (1997) The stability of amoxicillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother 39: 5–12PubMedCrossRefGoogle Scholar
  12. 12.
    Malanoski GJ, Eliopoulos GM, Ferraro MJ, Moellering RC Jr (1993) Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin. Eur J Clin Microbiol Infect Dis 12: 131–133PubMedCrossRefGoogle Scholar
  13. 13.
    Goddard AF, Jessa MJ, Barrett DA, Shaw PN, Idstrom JP, Cederberg C, Spiller RC (1996) Effect of omeprazole on the distribution of of metronidazole, amoxycillin and clarithromycin in human gastric juice. Gastroenterology 111: 358–367.PubMedCrossRefGoogle Scholar
  14. 14.
    Gustayson LE, Kaiser JF, Edmonds AL, Locks CS, DeBartolo ML, Schneck DW (1995) Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother 39: 2078–2083CrossRefGoogle Scholar
  15. 15.
    Harrison JD, Jones JA, Morris DL (1991) Azithromycin levels in plasma and gastric tissue, juice and mucus. Eur J Clin Microbiol Infect Dis 10: 862–864PubMedCrossRefGoogle Scholar
  16. 16.
    Blandizzi C, Malizia T, Gherardi G, Costa F, Marchi S, Marveggio C, Natale G, Senesi S, Bellini M, Maltini G et al (1998) Gastric mucosal distribution and clinical efficacy of azithromycin in patients with Helicobacter pylori related gastritis. J Antimicrob Chemother 42: 75–82PubMedCrossRefGoogle Scholar
  17. 17.
    Kees F, Holstege A, Ittner KP, Zimmermann M, Lock G, Scolmerich J, Grobecker H (2000) Pharmacokinetic interaction between proton pump inhibitors and roxithromycin in volunteers. Aliment Pharmacol Ther 14: 407–412PubMedCrossRefGoogle Scholar
  18. 18.
    Megraud F, Boyanova L, Lamouliatte H (1991) Activity of lansoprazole against Helicobacter pylori. Lancet 337: 1486CrossRefGoogle Scholar
  19. 19.
    Goodwin CS, Blake P, Blincow E (1986) The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis. J Antimicrob Chemother 17: 309–314PubMedCrossRefGoogle Scholar
  20. 20.
    Nagate T, Numata K, Hanada K, Kondo I (1990) The susceptibility of Campylobacter pylori to anti-ulcer agents and antibiotics. J Clin Gastroenterol 12 (suppl 1): S135–S138PubMedCrossRefGoogle Scholar
  21. 21.
    Midolo PD, Tumbridge JD, Lambert JR (1997) Bactericidal activity and synergy studies of proton pump inhibitors and antibiotics against Helicobacter pylori in vitro. J Antimicrob Chemother 39: 331–337PubMedCrossRefGoogle Scholar
  22. 22.
    Megraud F, Darmaillac V, Briigmann D (1995) Helicobacter pylori et azithromycine. Path Biol 43: 555–560Google Scholar
  23. 23.
    Malizia T, Tejada M, Marchetti F, Favini P, Pizzarelli G, Campa M, Senesi S (1998) Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study. Antimicrob Agents Chemother 41 (suppl B): 29–35Google Scholar
  24. 24.
    Cederbrant G, Kahlmeter G, Schalen C, Kamme C (1994) Additive effect of clarithromycin combined with 14-hydroxyclarithromycin, erythromycin, amoxicillin, metronidazole or omeprazole against Helicobacter pylori. J Antimicrob Chemother 34: 1025–1029CrossRefGoogle Scholar
  25. 25.
    Meyer TM, Ryu SY, Pendland SL, Danziger LH (1997)In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori. Antimicrob Agents Chemother 41: 1607–1608PubMedGoogle Scholar
  26. 26.
    Osato MS, Graham DY (1997) Ranitidine bismuth citrate enhances clarithromycin activity against clinical isolates of H. pylori. Gastroenterology 112: A1057Google Scholar
  27. 27.
    Midolo PD, Lambert JR, Ken TG (1997) Ranitidine bismuth citrate can overcome in vitro antibiotic resistance in Helicobacter pylori. Gut 41 (supp1.1): Al2Google Scholar
  28. 28.
    Megraud F, Roberts P, Williamsson R (2000) Ranitidine bismuth citrate can help overcome Helicobacter pylori resistance to clarithromycin in vivo. Helicobacter 5: 196–201PubMedCrossRefGoogle Scholar
  29. 29.
    Sorberg M, Hanberger H, Nilsson M, Nilsson LE (1997) Pharmacodynamic effects of antibiotics and acid pump inhibitors on Helicobacter pylori. Antimicrob Agents Chemother 41: 2218–2223Google Scholar
  30. 30.
    Weisblum B (1995) Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother 39: 577–585PubMedCrossRefGoogle Scholar
  31. 31.
    Debets-Ossenkopp YJ, Sparrius M, Kusters JG, Kolkman JJ, Vandenbroucke-Grauls CMJE (1996) Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori. FEMS Microbiol Lett 142: 37–42PubMedCrossRefGoogle Scholar
  32. 32.
    Hulten K, Gibreel A, Sköld O, Engstrand L (1997) Macrolide resistance in Helicobacter pylori: Mechanism and stability in strains from clarithromycin-treated patients. Antimicrob Agents Chemother 41: 2550–2553PubMedGoogle Scholar
  33. 33.
    Sigmund CD, Morgan EA (1992) Erythromycin resistance due to a mutation in a ribosomal RNA of Escherichia coli. Proc Nail Acad Sci USA 79: 5602–5606CrossRefGoogle Scholar
  34. 34.
    Versalovic J, Shortridge D, Kliber K, Griffy V, Beyer J, Flamm RK, Tanaka SK, Graham DY, Go MF (1996) Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 40: 477–480PubMedGoogle Scholar
  35. 35.
    Taylor DE, Ge Z, Purych D, lo T, Hiratsuka K (1997) Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. Antimicrob Agents Chemother 41: 2621–2628PubMedGoogle Scholar
  36. 36.
    Occhialini A, Urdaci M, Doucet-Populaire F, Bebear CM, Lamouliatte H, Megraud F (1997) Macrolide resistance in Helicobacter pylori: rapid detection of point mutations and assays of macrolide binding to ribosomes. Antimicrob Agents Chemother 41: 2724–2728PubMedGoogle Scholar
  37. 37.
    Debets-Ossenkopp YJ, Brinkman AB, Kuipers EJ, Vandenbroucke-Grauls CMJE, Kusters JG (1998) Explaining the bias in the 23S rRNA gene mutations asociated with clarithromycin resistance in clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother 42: 2749–2751PubMedGoogle Scholar
  38. 38.
    Wang GE, Rahman SM, Humayun MZ, Taylor DE (1999) Multiplex sequence analysis demonstrates the competitive growth advantage of the A-to-G mutants of clarithromycin-resistant Helicobacter pylori. Antimicrob Agents Chemother 43: 683–685PubMedCrossRefGoogle Scholar
  39. 39.
    Versalovic J, Osato MS, Spakovsky K, Dore MP, Reddy R, Stone GG, Shortridge D, Flamm RK, Tanaka SK, Graham DY (1997) Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J Antimicrob Chemother 40: 283–286PubMedCrossRefGoogle Scholar
  40. 40.
    van Doom LJ, Glupczynski Y, Kusters JG, Megraud F, Midolo P, Piffaretti JC, Queiroz D, Nouhan N, Stet E, Quint W (2001) Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S RNA gene. Multicenter validation study. Antimicrob Agents Chemother 45: 1500–1504CrossRefGoogle Scholar
  41. 41.
    Garcia-Arata MI, Baquero F, de Rafael L, de Argila CM, Gisbert JP, Mermjo F, Boixeda D Canton R (1999) Mutations in 23S rRNA in Helicobacter pylori conferring resistance to erythromycin do not always confer resistance to clarithromycin. Antimicrob Agents Chemother 43: 374–376PubMedGoogle Scholar
  42. 42.
    Alm RA, Ling LSL, Moir DT, King BL, Brown ED, Doig PC, Smith DR, Noonan B, Guild BC, deJonge BL et al (1999) Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 397: 176–180Google Scholar
  43. 43.
    Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, Fleischman RD, Ketchum KA, Klenk HP, Gill S, Dougherty BA et al (1997) The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 388: 539–547Google Scholar
  44. 44.
    Stone GG, Shortridge D, Versalovic J, Flamm RK, Beyer J, Ghoneim AT, Graham DY, Tanaka SK (1997) A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. Antimicrob Agents Chemother 41: 712–714PubMedGoogle Scholar
  45. 45.
    Marais A, Monteiro L, Occhialini A, Pina M, Lamouliatte H, Megraud F (1999) Direct detection of Helicobacter pylori resistance to macrolides by a polymerase chain reaction/DNA enzyme immunoassay in gastric biopsy specimens. Gut 44: 463–467PubMedCrossRefGoogle Scholar
  46. 46.
    Maeda S, Yoshida H, Matsunaga H, Ogura K, Kawamata O, Shiratori Y, Omata M (2000) Detection of clarithromycin-resistant H. pylori strains by a preferential homoduplex formation assay. J Clin Microbiol 38: 210–214PubMedGoogle Scholar
  47. 47.
    Matsuoka M, Yoshida Y, Hayakawa K, Fukuchi S, Sugona K (1999) Simultaneous colonisation of Helicobacter pylori with and without mutations in the 23S rRNA gene in patients with no history of clarithromycin exposure. Gut 45: 503–507PubMedCrossRefGoogle Scholar
  48. 48.
    Haas CE, Nix DE, Schentag JJ (1990) In vitro selection of resistant Helicobacter pylori. Antimicrob Agents Chemother 34: 1637–1641PubMedCrossRefGoogle Scholar
  49. 49.
    Martinez JL, Baquero F (2000) Mutation frequencies and antibiotic resistance. Antimicrob Agents Chemother 44: 1771–1777PubMedCrossRefGoogle Scholar
  50. 50.
    Burucoa C, Blasac G, Solnick JV, Fauchere JL (2000) Helicobacter pylori: une bacterie spontanement hypermutatrice? Lett Infect 15 (suppl 3): 30Google Scholar
  51. 51.
    Lenski RE (1997) The cost of antibiotic resistance from the perspective of a bacterium. Ciba Found Symp 207: 131–140PubMedGoogle Scholar
  52. 52.
    Megraud F, Camou-Juncas C, Occhialini A, Birac C (1996) Helicobacter pylori resistance levels to clarithromycin remain stable. Gastroenterology 110 (4):A192Google Scholar
  53. 53.
    Xia H, Buckley M, Keane CT, O’Morain CA (1996) Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitro. J Antimicrob Chemother 37: 473–481CrossRefGoogle Scholar
  54. 54.
    Bina JE, Alm RA, Uria-Nickelsen M, Thomas SR, Trust Ti, Hancock REW (2000) Helicobacter pylori uptake and efflux: Basis for intrinsic susceptibility to antibiotics in vitro. Antimicrob Agents Chemother 44: 248–254PubMedCrossRefGoogle Scholar
  55. 55.
    Seppala H, Klaukka T, Vuopio-Varkila J, Muotiala A, Helenius DH, Lager K, Huovinen P (1997) The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 337: 441–446PubMedCrossRefGoogle Scholar
  56. 56.
    Megraud F (1998) Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology 115: 1278–1282PubMedCrossRefGoogle Scholar
  57. 57.
    Broutet N, Guillon F, Sauty E, Lethuaire D, Megraud F (1998) Survey of the in vitro susceptibility of Helicobacter pylori to antibiotics in France. Preliminary results. Gut 43 (suppl.2): AllGoogle Scholar
  58. 58.
    Megraud F, Lehn N, Lind T, Bayerdorffer E, O’Morain C, Spiller R, Unge P, van Zanten SV, Wrangstadh M, Burman CF (1999) Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial. The MACH 2 study. Antimicrob Agents Chemother 43: 2747–2752PubMedGoogle Scholar
  59. 59.
    van Zwet AA, de Boer WA, Schneeberger PM, Weel J, Jansz AR, Thijs JC (1996) Prevalence of primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Netherlands. Eur J Clin Microbiol Infect Dis 15: 861–864CrossRefGoogle Scholar
  60. 60.
    Debets-Ossenkopp YJ, Herscheid AJ, Pot RGJ, Kuipers EJ, Kusters JG, Vandenbroucke-Grauls CMJE (1999) Prevalence of resistance to metronidazole, clarithromycin, amoxicillin, tetracycline and trovafloxacin in Helicobacter pylori in The Netherlands. J Antimicrob Chemother 43: 511–515PubMedCrossRefGoogle Scholar
  61. 61.
    Glupczynski Y, Megraud F, Lopez-Brea M, Andersen LP (2001) Zool-Results of a multicenter European Survey of in vitro antibacterial resistance in Heliobacter pylori (1997–1998) Eur J Clin Microbiol Inf Dis (in press) Google Scholar
  62. 62.
    Weissfeld A, Haber M, Rose P, Kidd S, Siepman N (1997) Geographical distribution in the United States of primary resistance to clarithromycin and metronidazole in patients infected with Helicobacter pylori. Gastroenterology 112: A328Google Scholar
  63. 63.
    de Koster E, Cozzoli A, Vandenbroucke C, Jonas C, Denis P, Oters J, Deltenre M (1997) Helicobacer pylori resistance to macrolides increases, to imidazole remains stable. Gastroenterology 112: A99Google Scholar
  64. 64.
    Morton D, Bardhan KD (1998) A six-year assessment of tinidazole, metronidazole, clarithromycin, tetracycline and amoxicillin resistance in Helicobacter pylori clinical isolates: a rising tide of antibiotic resistance? Gastroenterology 114: A235Google Scholar
  65. 65.
    Wurzer H, Rodrigo L, Stamler D, Archambault A, Rokkas T, Skandalis N, Fedorak R, Bazzoli F, Hentschel E, Mora P et al (1997) Short-course therapy with amoxicillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group. Aliment Pharmacol Ther 11: 943–952PubMedCrossRefGoogle Scholar
  66. 66.
    Laurent J, Megraud F, Flejou JF, Caekert A, Barthelemy P (2001) A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther in pressGoogle Scholar
  67. 67.
    NCCLS (1999) Performance standards for antimicrobial susceptibility testing. VIth Informational supplement. M100S9 19,1Google Scholar
  68. 68.
    Glupczynski Y (1998) Toward standardisation of antimicrobial susceptibility testing of H. pylori: preliminary results by a European multicentre study group. Gut 43 (suppl 2): A47Google Scholar
  69. 69.
    Glupczynski Y, Labbe M, Hansen W, Crokaert F, Yourassowsky E (1991) Evaluation of the Etest for quantitative antimicrobial susceptibility testing of Helicobacter pylori. J Clin Microbiol 29: 2072–2075Google Scholar
  70. 70.
    Piccolomini R, Di Bonaventura G, Catamo G, Carbone F, Neri M (1997) Comparative evaluation of the Etest, agar dilution, and broth microdilution for testing susceptibilities of Helicobacter pylori strains to 20 antimicrobial agents. J Clin Microbiol 35: 1842–1846PubMedGoogle Scholar
  71. 71.
    Fauchere JL, Burucoa C, Grignon B (2000) Tests in vitro de la sensibilite de Helicobacter pylori aux antibiotiques. Lett Infect 15 (suppl): 5–6Google Scholar
  72. 72.
    Szczebara F, Dhaemens L, Vincent P, Husson MO (1997) Evaluation of rapid molecular methods for detection of clarithromycin resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 16: 162–164CrossRefGoogle Scholar
  73. 73.
    Alarcon T, Domingo D, Prieto N, Lopez-Brea M (2000) PCR using 3’-mismatched primers to detect A2142C mutation in 23S rRNA conferring resistance to clarithromycin in Helicobacter pylori clinical isolates. J Clin Microbiol 38: 923–925PubMedGoogle Scholar
  74. 74.
    Pina M, Occhialini A, Monteiro L, Doermann HP, Megraud F (1998) Detection of point mutations associated with resistance of Helicobacter pylori to clarithromycin by hybridization in liquid phase. J Clin Microbiol 36: 3285–3290PubMedGoogle Scholar
  75. 75.
    van Doom LJ, Debets-Ossenkopp YJ, Marais A, Sanna R, Megraud F, Kusters JG, Quinnt WGV (1999) Rapid detection, by PCR and reverse hybridization, of mutations in the Helicobacter pylori 23S rRNA gene, associated with macrolide resistance. Antimicrob Agents Chemother 43: 1779–1782Google Scholar
  76. 76.
    Wittwer CT, Ririe KM, Andrew RV, David DA, Gundry RA, Balis UJ (1997) The LightcyclerTM: a microvolume multisample fluorimeter with rapid temperature control. BioTechniques 22: 176–181PubMedGoogle Scholar
  77. 77.
    Gibson JR, Saunders NA, Burke B, Owen RI (1999) Novel method for rapid determination of clarithromycin sensitivity in Helicobacter pylori. J Clin Microbiol 37: 3746–3748Google Scholar
  78. 78.
    Trebesius K, Panthel K, Strobel S, Vogt K, Faller G, Kirchner T, Kist M, Heeseman J, Haas R (2000) Rapid and specific detection of Helicobacter pylori macrolide resistance in gastric tissue by fluorescent in situ hybridisation. Gut 46: 608–614PubMedCrossRefGoogle Scholar
  79. 79.
    Bergeron MG, Ouelette M (1998) Preventing antibiotic resistance through rapid genotypic identification of bacteria and of their antibiotic resistance genes in the clinical microbiology laboratory. J Clin Microbiol 36: 2169–2172PubMedGoogle Scholar
  80. 80.
    Lamouliatte H, Megraud F, de Mascarel A, Quinton A (1987) Placebo-controlled trial of josamycin in Campylobacter pylori associated gastritis. In: Kaijser B, Falsen E (eds) Campylobacter IV. University of Goteborg, Goteborg, 388–389Google Scholar
  81. 81.
    Glupczynski Y, Burette A (1990) Failure of azithromycin to eradicate Campylobacter pylori from the stomach because of acquired resistance during treatment. Am J Gastroenterol 85: 98–99PubMedGoogle Scholar
  82. 82.
    McNulty CA, Gearty JC, Crump B, Davis M, Donovan IA, Melikian V, Lister DM, Wise R (1986) Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br Med J 293: 645–649CrossRefGoogle Scholar
  83. 83.
    Graham DY, Opekun AR, Klein PD. (1993) Clarithromycin for the eradication of Helicobacter pylori. J Clin Gastroenterol 16: 292–294PubMedCrossRefGoogle Scholar
  84. 84.
    Axon ATR, Moayyedi P (1996) Eradication of Helicobacter pylori: omeprazole in combination with antibiotics. Scand J Gastroenterol 31 (suppl 215): 82–89CrossRefGoogle Scholar
  85. 85.
    Bazzoli F, Zagari RM, Fossi S, Pozzato P, Roda A, Roda E (1993) Efficacy and tolerability of a short term, low dose triple therapy for eradication of Helicobacter pylori. Gastroenterology 104: A40Google Scholar
  86. 86.
    Lamouliatte H, Cayla R, Megraud F, Zerbib F, Stablo M, Bouchard S, Quinton A (1993) Amoxicillin-clarithromycin-omeprazole: the best therapy for Helicobacter pylori infection? Acta Gastroenterol Belg 56: 140Google Scholar
  87. 87.
    Lind T, van Zanten SV, Unge P, Spitler R, Bayerdorffer E, O’Morain C, Bardhan KD, Bradette M, Chiba N, Wrangstadh M et al. (1996) Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH1 study. Helicobacter 3: 138–144CrossRefGoogle Scholar
  88. 88.
    Lind T, Megraud F, Unge P, Bayerdorffer E, O’Morain C, Spitler R, van Zanten SV, Bardhan Hellblom M, Wrangstadh M et al (1999) The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 116: 248–253PubMedCrossRefGoogle Scholar
  89. 89.
    The European Helicobacter pylori Study Group.Current European concepts on the management of Helicobacter pylori infection. (1997) The Maastricht Consensus Report. Gut 41:8–13Google Scholar
  90. 90.
    The Report of the Digestive Health Initiative International Update Conference on Helicobacter pylori (1997) Gastroenterology 113 (suppl): S4–S8Google Scholar
  91. 91.
    Lam SK, Talley NJ (1998) Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 13: 1–12PubMedCrossRefGoogle Scholar
  92. 92.
    Huang JQ, Hunt RH (1999) The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxicillin or metronidazole. Aliment Pharmacol Ther 13: 719–729PubMedCrossRefGoogle Scholar
  93. 93.
    Calvet X, Garcia N, Lopez T, Gisbert JP, Gene E, Roque M (2000) A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxicillin for treating Helicobacter pylori infections. Aliment Pharmacol Ther 14: 603–609PubMedCrossRefGoogle Scholar
  94. 94.
    Delchier JC, Roudot-Thoraval F, Guisau IM et le Groupe d’Etudes Francais de Helicobacters (GEFH) (2000) Evaluation de 1’ efficacite du traitement eradicateur de (’infection a Helicobacter pylori en France: resultats preliminaires de I’ enquete du GEFH. Lett Infect 15 (suppl): 9–10Google Scholar
  95. 95.
    Moayyedi P, Feltbower R, Crocombe W, Mason S, Athas P, Brown J, Dowell AC, Richards IDG, Axon ATR on behalf of the Leeds Help Study Group (2000) The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme. Aliment Pharmacol Ther 14: 719–728CrossRefGoogle Scholar
  96. 96.
    Lamouliatte H and the Aquitaine Gastro Association, Samoyeau R, de Mascarel A, Megraud F (1999) Double versus single dose of pantoprazole in combination with clarithromycin and amoxicillin for 7 days in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 13: 1523–1530CrossRefGoogle Scholar
  97. 97.
    Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY (2000) Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy- A meta-analytical approach. Dig Dis Sci 45: 68–76PubMedCrossRefGoogle Scholar
  98. 98.
    Houben MHMG, van de Beek D, Hensen EF, De Craen JM, Rauws EAJ, Tytgat GNJ (1999) A systematic review of Helicobacter pylori eradication therapy-the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 13: 1047–1056PubMedCrossRefGoogle Scholar
  99. 99.
    Broutet N, Tchamgoue S, Pereira E, Megraud F (2000) Risk factors for failure of Helicobacter pylori therapy. In: Hunt RH, Tytgat GNJ. Helicobacter pylori: Basic mechanisms to clinical cure (2000) Kluwer, Dordrecht, 601–607Google Scholar
  100. 100.
    Dohmen W, Seelis REA (1998) The role of azithromycin in the treatment of Helicobacter pylori infection. A retrospective report. Infection 28: 256–261CrossRefGoogle Scholar
  101. 101.
    LaMe L, Stein C, Garcia F, Trujillo M, Estrada R (1996) Prospective evaluation of the macrolide antibiotic dirithromycin for the treatment of Helicobacter pylori. Aliment Pharmacol Ther 10: 269–273CrossRefGoogle Scholar
  102. 102.
    Adamsson I, Nord CE, Lundquist P, Sjostedt S, Edlund C (1999) Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients. J Antimicrob Chemother 44: 629–640PubMedCrossRefGoogle Scholar

Copyright information

© Springer Basel AG 2002

Authors and Affiliations

  • Francis Mégraud
    • 1
  1. 1.Laboratoire de BactériologieHôpital PellegrinBordeaux cedexFrance

Personalised recommendations